Digital Diagnostics, formerly known as IDx, is a leading AI diagnostics company that develops clinically-aligned autonomous algorithms that detect disease in medical images.
Digital Diagnostics is on a mission to transform the quality, accessibility, and affordability of healthcare.
Digital Diagnostics was founded in 2010 by Michael Abramoff. The commpany is based in Coralville, Iowa.
Digital Diagnostics is committed to autonomous AI the right way: with an unwavering focus on improving patient outcomes, safety, efficacy and equity.
Digital Diagnostics developed developed a unique, patented biomarker-based approach to build AI algorithms that perform cognitively complex tasks. These algorithms are integrated into easy-to-use systems that can make instantaneous clinical decisions in which the computer makes the medical decision.
Digital Diagnostics and its flagship product IDx-DR, an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, has proven that intelligent diagnostic platforms can be used safely, efficiently and equitably to improve patient outcomes.
Digital Diagnostics also develops additional artificial intelligence-based diagnostic algorithms for the detection of macular degeneration, glaucoma, Alzheimer's disease, cardiovascular disease, and stroke risk.
Digital Diagnostics has worked collaboratively within the healthcare and regulatory systems of multiple countries, including U.S. federal agencies, to accelerate the acceptance and adoption of ethical, evidence-based, autonomous AI.
Digital Diagnostics is backed 8VC, Optum Ventures, Alpha Edison, Heritage Provider Network, Leach Capital, LLC, and others. The company has raised a total of $64.6M to date. Digital Diagnostics has also acquired 3Derm Systems in Aug 19, 2020.